GILD
The analyst note in plain English
RBC Capital basically told Gilead: nice start, but don’t get too comfortable. The firm reiterated a Sector Perform rating on GILD and slapped a $123 price target on the stock — below where shares are already trading around $139.77. So if you’re holding the bag here, this is less “new rally fuel” and more “let’s not pretend this is a straight line to the moon.”
Yeztugo is the star, but it’s not a clean victory lap
The real nugget in the note is Yeztugo, Gilead’s twice-yearly HIV prevention drug. RBC said prescription trends suggest a sizeable first-quarter beat versus sell-side consensus, which is the kind of thing that can make investors lean in fast. But there’s a catch, because there’s always a catch: the firm also pointed to variability, shifting capture rates, and initial persistence likely around or below 70% based on recent doctor checks.
Why you should care
That combo matters because this isn’t just about one flashy launch. If uptake is strong but patients don’t stick around the way bulls hope, the market may need to temper its expectations. In other words, Yeztugo might be pulling ahead of the model, but the runway still has some potholes.
Big picture
Gilead is still building a bigger story around HIV prevention, and the company’s recent access push — with the U.S. State Department, PEPFAR, and The Global Fund backing wider reach — adds another layer of momentum. But for now, RBC’s message is simple: promising launch, yes; clean victory lap, not yet.